The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease
Open accessAbstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons of the substantia nigra pars compacta (SNpc). Although various treatments are successfully used to alleviate the symptoms of PD, none of them prevents or halts the neurodegenerative process of the disease. Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of proteins, supports the survival and the differentiation of dopaminergic neurons. BDNF also prevents the death of dopaminergic neurons in vitro, which suggests that it may be of possible use in the development of neuroprotective therapies for PD. To determine whether BDNF is neuroprotective for SNpc dopaminergic neurons in the adult brain, we used a rat model of PD in which degeneration of 60-70% of these neurons was induced by an intrastriatal injection of 6-hydroxydopamine (6-OHDA). We report here that intrastriatal grafts of fibroblasts genetically engineered to produce BDNF partially prevent the loss of nerve terminals and completely prevent the loss of cell bodies of the nigrostriatal dopaminergic pathway that is induced by the intrastriatal injection of 6-OHDA. In contrast, the implantation of control fibroblasts that did not produce BDNF failed to protect nerve terminals and cell bodies against 6-OHDA-induced damage. Our observation that grafts of BDNF-producing fibroblasts protect against 6-OHDA-induced degeneration of SNpc dopaminergic neurons in the adult rat brain opens new perspectives for treatments aimed at the prevention of neurodegeneration in PD, using gene therapy and neurotrophic factors such as BDNF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vast majority of studies with BDNF administration before induction of parkinsonism, the research results revealed at least partial prevention of neuronal cell loss [89,90,92,93,99,101].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585
Estimation of nuclear population from microtome sections
Abercrombie, M. (1946) · The Anatomical Record · doi:10.1002/ar.1090940210 · Cited by 4,363
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Gerfen, C. R., Herkenham, M. A., & Thibault, J. (1987) · Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 804
Neurotrophic factors: from molecule to man
Lindsay, R. M., Wiegand, S. J., Altar, C. A., & DiStefano, P. S. (1994) · Trends in Neurosciences · doi:10.1016/0166-2236(94)90099-x · Cited by 789
Sendtner, M., Holtmann, B., Kolbeck, R., Thoenen, H., & Barde, Y. (1992) · Nature · doi:10.1038/360757a0 · Cited by 706
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
Knüsel, B., Winslow, J. W., Rosenthal, A., Burton, L. E., Seid, D. P., Nikolics, K., & Hefti, F. F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.961 · Cited by 601
Research works printed but not linked: 1
- Jackson-Lewis V, Jakowec M, Burke RE, Przedbroski S (1995) Time course and morphology of dopaminergic neuronal death caused by neurotoxin I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurode- generation, in press.
Cited by
Sorted by citations
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
The impact of age, weight and gender on BDNF levels in human platelets and plasma
Lommatzsch, M., Zingler, D., Schuhbaeck, K., Schloetcke, K., Zingler, C., Schuff‐Werner, P., & Virchow, J. C., Jr. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.002 · Cited by 849
Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640
BDNF mediates adaptive brain and body responses to energetic challenges
Marosi, K., & Mattson, M. P. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.10.006 · Cited by 568
Prospects for new restorative and neuroprotective treatments in Parkinson's disease
Dunnett, S. B., & Björklund, A. (1999) · Nature · doi:10.1038/399a032 · Cited by 543
The role of neuronal growth factors in neurodegenerative disorders of the human brain
Connor, B. J., & Dragunow, M. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00004-6 · Cited by 538
Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra
Howells, D. W., Porritt, M. J., Wong, J. Y. F., Batchelor, P. E., Kalnins, R., Hughes, A. J., & Donnan, G. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7483 · Cited by 513
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_19 · Cited by 518
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., & Nagatsu, T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00463-2 · Cited by 404
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 371
Baquet, Z. C., Bickford, P. C., & Jones, K. R. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4601-04.2005 · Cited by 318
Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., & Teixeira, A. L. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5357-2 · Cited by 299
Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
Alexi, T. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00032-5 · Cited by 296
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O. S., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson-Lewis, V. R., & Przedborski, S. (2002) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 276
Self-citationTyrosine Hydroxylase and Parkinson’s Disease
Haavik, J., & Toska, K. (1998) · Molecular Neurobiology · doi:10.1007/bf02741387 · Cited by 263
Chang, J. W., Wachtel, S. R., Young, D., & Kang, U. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00217-6 · Cited by 248
Self-citationNeuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF
Cohen, A. D., Tillerson, J. L., Smith, A. D., Schallert, T., & Zigmond, M. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01657.x · Cited by 243
Marosi, K., Kim, S. W., Moehl, K., Scheibye‐Knudsen, M., Cheng, A., Cutler, R., Camandola, S., & Mattson, M. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13868 · Cited by 242
Human neural stem cells genetically modified for brain repair in neurological disorders
Kim, S. (2004) · Neuropathology (Kyoto. 1993) · doi:10.1111/j.1440-1789.2004.00552.x · Cited by 225
Kramer, E. R., Aron, L., Ramakers, G. M. J., Sabine, S., Zhuang, X., Beyer, K., Smidt, M. P., & Klein, R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050039 · Cited by 212
Emerich, D. F., Lindner, M. D., Winn, S. R., Chen, E., Frydel, B. R., & Kordower, J. H. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-16-05168.1996 · Cited by 202
Role of MicroRNAs in Parkinson’s Disease
Goh, S. Y., Chao, Y., Dheen, S. T., Tan, E., & Tay, S. S. W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225649 · Cited by 179
Tissue engineering: generation of differentiated artificial tissues for biomedical applications
Minuth, W. W., Sittinger, M., & Kloth, S. (1997) · Cell and Tissue Research · doi:10.1007/s004410050974 · Cited by 171
Teixeira, A. L., Barbosa, I. G., Diniz, B. S., & Kümmer, A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.111 · Cited by 164
Hu, Y., & Russek, S. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05237.x · Cited by 164
Neurotrophic factor therapy for Parkinson’s disease
Rangasamy, S. B., Soderstrom, K. E., Bakay, R. A. E., & Kordower, J. H. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84013-0 · Cited by 155
Sun, M., Kong, L., Wang, X., Lu, X.-G., Gao, Q., & Geller, A. I. (2005) · Brain Research · doi:10.1016/j.brainres.2005.05.072 · Cited by 154
Berger, B., Grissac, N. D., & Alvarez, C. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990118)403:3 · Cited by 16
Costantini, L. C., Bakowska, J. C., Breakefield, X. O., & Ole Isacson, A. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301119 · Cited by 142
Brain-derived neurotrophic factor
Benarroch, E. E. (2015) · Neurology · doi:10.1212/wnl.0000000000001507 · Cited by 138
Porritt, M. J., Batchelor, P. E., & Howells, D. W. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.030 · Cited by 135
Brain-derived neurotrophic factor as a drug target for CNS disorders
Pezet, S., & Malcangio, M. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.391 · Cited by 132
Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease
Fumagalli, F., Racagni, G., & Riva, M. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500360 · Cited by 135
Balaratnasingam, S., & Janča, A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.006 · Cited by 133
Low BDNF is associated with cognitive impairments in patients with Parkinson’s disease
Wang, Y., Liu, H. S., Zhang, B., Soares, J. C., & Zhang, X. Y. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.05.023 · Cited by 129
Park, H., Lim, S., Joo, W. S., Yin, C.-S., Lee, H., Lee, H., Seo, J.-C., Leem, K., Son, Y.-S., Kim, Y.-J., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(02)00031-6 · Cited by 129
Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer
Klein, R. L., Lewis, M. H., Muzyczka, N., & Meyer, E. M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)02116-2 · Cited by 128
Géral, C., Angelova, A., & Lesieur, S. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5010127 · Cited by 126
Zhu, G., Li, J., He, L., Wang, X., & Hong, X. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13061 · Cited by 118
Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor
Chen, M., Valenzuela, R. M., & Dhib-Jalbut, S. S. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00177-1 · Cited by 118
Bencsics, C. E., Wachtel, S. R., Milstien, S., Hatakeyama, K., Becker, J. B., & Kang, U. J. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04449.1996 · Cited by 109
Self-citationJollivet, C., Aubert‐Pouëssel, A., Clavreul, A., Venier‐Julienne, M., Remy, S., Montero‐Menei, C. N., Benoît, J., & Meneï, P. (2003) · Biomaterials · doi:10.1016/s0142-9612(03)00601-x · Cited by 103
Liang, X., Liu, X., Li, F.-Q., Luo, Y., Lü, J., Zhang, W.-M., Wang, X.-M., & Han, J.-S. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00513-2 · Cited by 105
Batchelor, P., Liberatore, G. T., Porritt, M. J., Donnan, G. A., & Howells, D. W. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00239.x · Cited by 105
Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease
Hou, L., Chen, W., Liu, X., Qiao, D., & Zhou, F.-M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00358 · Cited by 112
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Wrage, P. C., Keefer, E. W., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.10.011 · Cited by 104
Bdnf gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro
Volpicelli, F., Caiazzo, M., Greco, D., Consales, C., Leone, L., Perrone‐Capano, C., D’Amato, L. C., & di Porzio, U. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04494.x · Cited by 100
Hagg, T. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6684 · Cited by 98
Experimental models of Parkinson's disease: insights from many models.
Tolwani, R. J., Jakowec, M. W., Petzinger, G. M., Green, S. L., & Waggie, K. S. (1999) · PubMed · Cited by 96
Lin, C., Lin, Y.-C., Huang, C.-Y., Wu, S.-R., Chen, C., & Liu, H.-L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.044 · Cited by 94
Loh, N. K., Woerly, S., Bunt, S. M., Wilton, S. D., & Harvey, A. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7692 · Cited by 91
Emerich, D. F., Cain, C. K., Greco, C., Saydoff, J. A., Hu, Z. Y., Liu, H., & Lindner, M. D. (1997) · Cell Transplantation · doi:10.1016/s0963-6897(97)00035-3 · Cited by 91
Therapeutic Potential of Nerve Growth Factors in Parkinson??s Disease
Collier, T. J., & Sortwell, C. E. (1999) · Drugs & Aging · doi:10.2165/00002512-199914040-00003 · Cited by 92
Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases
Levy, Y. S., Gilgun‐Sherki, Y., Melamed, E., & Offen, D. (2005) · BioDrugs · doi:10.2165/00063030-200519020-00003 · Cited by 92
Pathogenesis of Parkinson's Disease: Prospects of Neuroprotective and Restorative Therapies
Fernández‐Espejo, E. (2004) · Molecular Neurobiology · doi:10.1385/mn:29:1:15 · Cited by 88
Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis
Jiang, L., Zhang, H., Wang, C., Ming, F., Shi, X., & Yang, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.07.010 · Cited by 88
Zloković, B. V., & Apuzzo, M. L. J. (1997) · Neurosurgery · doi:10.1097/00006123-199704000-00027 · Cited by 83
Adult Hippocampal Neurogenesis in Parkinson’s Disease: Impact on Neuronal Survival and Plasticity
Regensburger, M., Prots, I., & Winner, B. (2014) · Neural Plasticity · doi:10.1155/2014/454696 · Cited by 90
Neuroprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson's disease
Kim, M. ‐., Lee, J., Lee, W. Y., & Kim, S. (2004) · Phytotherapy Research · doi:10.1002/ptr.1486 · Cited by 84
Ghrelin: A link between ageing, metabolism and neurodegenerative disorders
Stoyanova, I. I. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.026 · Cited by 84
Role of BDNF in Central Motor Structures and Motor Diseases
He, Y., Zhang, X., Yung, W., Zhu, J., & Wang, J. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8466-y · Cited by 84
Matarredona, E. R., Santiago, M., Venero, J. L., Cano, J., & Machado, A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00056.x · Cited by 81
Blaha, G. R., Raghupathi, R., Saatman, K. E., & McIntosh, T. K. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00214-1 · Cited by 80
Baydyuk, M., Nguyen, M. T., & Xu, B. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.12.018 · Cited by 80
Physical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
Lü, X., & Hagg, T. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19971124)388:3 · Cited by 79
Xiao, M.-F., Xu, J.-C., Tereshchenko, Y., Novak, D., Schachner, M., & KLEENE, R. B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4860-09.2009 · Cited by 78
Visanji, N. P., Orsi, A., Johnston, T. H., Howson, P. A., Dixon, K., Callizot, N., Brotchie, J. M., & Rees, D. D. (2008) · The FASEB Journal · doi:10.1096/fj.07-095398 · Cited by 78
Genetically engineered human neural stem cells for brain repair in neurological diseases.
Kim, S. (2007) · Brain & development (Tokyo. 1979) · doi:10.1016/j.braindev.2006.07.012 · Cited by 92
Halbach, O. V. B. U., Minichiello, L., & Unsicker, K. (2005) · The FASEB Journal · doi:10.1096/fj.05-3845fje · Cited by 79
Mangano, E. N., Peters, S., Litteljohn, D., So, R., Bethune, C., Bobyn, J., Clarke, M., & Hayley, S. P. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.011 · Cited by 75
Hernandez-Chan, N. G., Bannon, M. J., Orozco-Barrios, C. E., Escobedo, L., Zamudio, S., De la Cruz, F., Gongora-Alfaro, J. L., Armendáriz-Borunda, J., Reyes-Corona, D., Espadas-Alvarez, A. J., et al. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0166-7 · Cited by 73
Ex vivo gene therapy for the treatment of neurological disorders
Gowing, G., Svendsen, S. P., & Svendsen, C. N. (2017) · Progress in brain research · doi:10.1016/bs.pbr.2016.11.003 · Cited by 74
Localized cell and drug delivery for auditory prostheses
Hendricks, J. L., Chikar, J. A., Crumling, M. A., Raphael, Y., & Martin, D. C. (2008) · Hearing Research · doi:10.1016/j.heares.2008.06.003 · Cited by 73
Clark, J., Silvaggi, J. M., Kiselak, T., Zheng, K., Clore, E. L., Dai, Y., Bass, C. E., & Simon, D. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048925 · Cited by 70
Fukuhara, K., Ishikawa, K., Yasuda, S., Kishishita, Y., Kim, H.-K., Kakeda, T., Yamamoto, M., Norii, T., & Ishikawa, T. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9782-2 · Cited by 72
Intrastriatal and Intranigral Grafting of hNT Neurons in the 6-OHDA Rat Model of Parkinson's Disease
Baker, K. A., Hong, M. G. L., Sadi, D., & Méndez, I. (2000) · Experimental Neurology · doi:10.1006/exnr.1999.7337 · Cited by 70
Luellen, B. A., Bianco, L. E., Schneider, L., & Andrews, A. M. (2006) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2006.00279.x · Cited by 68
Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons
Feng, L., Wang, C.-Y., Jiang, H., Oho, C., Mizuno, K., Dugich‐Djordjevic, M. M., & Lu, B. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00015-7 · Cited by 66
Chmielarz, P., & Saarma, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00120-3 · Cited by 69
Thakker‐Varia, S., Behnke, J. A., Doobin, D. J., Dalal, V., Thakkar, K., Khadim, F., Wilson, E., Palmieri, A. J., Antila, H., Rantamäki, T., et al. (2014) · Stem Cell Research · doi:10.1016/j.scr.2014.03.005 · Cited by 69
Berg, J., Roch, M., Altschüler, J., Winter, C., Schwerk, A. M. K., Kurtz, A., & Steiner, B. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9551-y · Cited by 66
Li, X., Dai, C., Chen, L., Zhou, W., Han, H., & Dong, Z. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12555 · Cited by 67
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases
Gibrat, C., & Cicchetti, F. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.023 · Cited by 68
Angelucci, F., Piermaria, J., Gelfo, F., Shofany, J., Tramontano, M., Fiore, M., Caltagirone, C., & Peppe, A. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2015-0322 · Cited by 65
Pröschel, C., Stripay, J. L., Shih, C., Munger, J. C., & Noble, M. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302878 · Cited by 65
Dou, S.-H., Cui, Y., Huang, S.-M., & Zhang, B. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.924155 · Cited by 67
Cell Transplantation for Parkinson's Disease: Present Status
Drucker-Colı́n, R., & Verdugo‐Díaz, L. (2004) · Cellular and Molecular Neurobiology · doi:10.1023/b:cemn.0000022764.94760.3f · Cited by 62
Gardiner, J. C., Barton, D., Overall, R. L., & Marc, J. (2008) · The Neuroscientist · doi:10.1177/1073858408325269 · Cited by 62
Heckman, P. R. A., van Duinen, M. A., Bollen, E., Nishi, A., Wennogle, L. P., Blokland, A., & Prickaerts, J. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw030 · Cited by 63
Perreault, M. L., Fan, T., Alijaniaram, M., O’Dowd, B. F., & George, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033348 · Cited by 60
Mattson, M. P. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-130335 · Cited by 60
Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Kogure, O., Kuno, S., Ichinose, H., & Nagatsu, T. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01577-4 · Cited by 59
Shen, H., Marino, R. A. M., McDevitt, R. A., Bi, G.-H., Chen, K., Madeo, G., Lee, P.-T., Liang, Y., De Biase, L. M., Su, T.-P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800886115 · Cited by 58
Stahl, K., Mylonakou, M. N., Skare, Ø., Amiry-Moghaddam, M. R., & Torp, R. (2011) · Brain Research · doi:10.1016/j.brainres.2010.12.090 · Cited by 63
Role of glial cells in neurotoxin-induced animal models of Parkinson’s disease
Yokoyama, H., Uchida, H., Kuroiwa, H., Kasahara, J., & Araki, T. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0424-0 · Cited by 57
Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness
Khalin, I., Kocherga, G., Bakar, M. A., & Alyautdin, R. N. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s77480 · Cited by 61
Metadata
- Authors
- Levivier, M., Przedborski, S., Bencsics, C., & Kang, U.
- Affiliations
- Columbia University (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 1995-12-01
- Volume
- 15
- Issue
- 12
- Pages
- 7810-7820
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6577965
- OpenAlex
- W1590012920
- Cited by
- 274
- References
- 25
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 11 · 2019: 5 · 2018: 9 · 2017: 3 · 2016: 9 · 2015: 11 · 2014: 11 · 2013: 8 · 2012: 9
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Irving A. Hansen Memorial Foundation
- National Institutes of Health (5r29ns032080-05, 5k08ns001724-03)
- Parkinsonfonden
- Fogarty International Center
- National Institute of Neurological Disorders and Stroke (1-K08-NS01724-01, R29 NS32080)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, brain-derived neurotrophic factor, dopaminergic neuron loss, substantia nigra pars compacta, 6-hydroxydopamine, gene therapy, neuroprotection, nigrostriatal pathway, neurotrophic factors
- MeSH terms
- Animals, Autoradiography, Corpus Striatum, Dopamine, Fibroblasts, Genetic Engineering, Male, Nerve Degeneration, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Rats, Inbred F344, Oxidopamine, Brain-Derived Neurotrophic Factor, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
